Wuhan YZY Biopharma Co., Ltd. has announced the grant of options under its 2024 H Share Option Plan. On May 27, 2025, the company granted an aggregate of 3,550,000 options to subscribe for H Shares to four eligible participants. This move, which is aligned with the company's corporate governance practices, follows the adoption of the 2024 H Share Option Plan on June 27, 2024. The options are subject to a clawback mechanism, ensuring they can be reclaimed under certain conditions if the employment or service relationship is terminated. The announcement was made in compliance with Rule 17.06A of the Listing Rules.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.